Other Deal Trends 2026: Activity Surges 3400% in 6 Months

Thirty-four deals in six months where there were zero before — that's a 3400% increase in "other" category deal activity between the periods ending February 2026 and August 2026. This isn't a rounding error or a taxonomic quirk. What we're seeing is a structural reallocation of pharma BD capital toward non-traditional therapeutic modalities, platform technologies, and cross-sector assets that don't fit neatly into oncology, immunology, or CNS buckets. The catalyst: Big Pharma pipeline anxiety has moved beyond indication-level gaps into capability-level gaps, and companies are buying entire technology stacks rather than individual drug candidates.

The Data — Other Deal Activity, Period over Period

The zero-to-34 jump demands context. "Other" in deal databases typically captures transactions involving enabling technologies, diagnostics, protein engineering platforms, research tools, and multi-modality partnerships that span traditional therapeutic area classifications. A jump this sharp doesn't mean these assets didn't exist before — it means they weren't being transacted at this pace. The second half of 2026 represents a definitive inflection point in how pharma values non-drug assets.

What's Driving the Trend

Three forces converged to produce this spike. First, the AI-native biology thesis reached boardroom maturity. Generate:Biomedicines signing with Novartis in late June isn't just another partnership — it's validation that generative biology platforms have crossed the credibility threshold for top-10 pharma. When Novartis writes a deal for AI-designed molecules without a disclosed upfront, it signals confidence in the platform's long-term pipeline output, not a single asset bet. This pull-through effect is real: once one megapharma validates a platform category, competing BD teams scramble to secure similar assets before term sheets inflate.

Second, the Merck KGaA–Bio-Techne transaction at $11.3 billion total deal value represents something more fundamental than a licensing deal. This is a pharma company acquiring a research tools and protein sciences business — a move that blurs the line between drug development and drug enablement. Merck KGaA's bet is that controlling upstream biology (reagents, proteins, spatial biology platforms) creates durable competitive advantage in an era where every pharma company is trying to do the same thing: identify better targets faster. This deal alone accounts for a massive chunk of total deal value in the "other" category and likely triggered at least a handful of the remaining 30+ transactions as companies reassessed what they consider strategic.

Third, geographic diversification of licensing sources is accelerating. YaoPharma–Pfizer at $150M upfront and $2.05B total deal value reflects Pfizer's continued bet on sourcing differentiated assets from Chinese biotechs. The "other" classification here likely reflects a multi-asset or platform deal that doesn't slot into a single therapeutic area. Pfizer's willingness to pay $150M upfront for a Chinese-origin asset — in the current geopolitical climate — tells you how acute the pipeline pressure is. Companies are looking everywhere, and they're moving fast. You can compare this upfront against historical Deal Benchmarks for deals of similar scope.

Notable Deals

The Bio-Techne–Merck KGaA transaction dominates this table and, frankly, dominates the entire "other" deal category for 2026. Multiple reporting entries across late June reflect the staged disclosure of deal economics — the headline TDV settling at $11.3B. This is the largest research tools acquisition in biopharma history by a wide margin. It signals that Merck KGaA views spatial biology, proteomics, and advanced reagent platforms as core strategic assets, not ancillary purchases. If you're a biotech with enabling technology platforms, this is your best comparable — and your best argument for premium valuation.

The Generate:Biomedicines–Novartis deal is notable precisely because of its undisclosed terms. Novartis has historically been aggressive in AI-biology partnerships (recall the 2023 Isomorphic Labs deal). An undisclosed structure here may indicate equity-linked components, option-based architectures, or programmatic frameworks that are difficult to summarize in a single TDV figure. BD teams should note: platform deals increasingly resist the upfront-plus-milestones template. Flexible structures are the norm for other licensing 2026 transactions.

YaoPharma's deal with Pfizer at $2.05B TDV stands out for its relatively conventional structure — $150M upfront with biobucks scaling to $2B. This is a 7.3% upfront-to-TDV ratio, which is on the lower end for cross-border deals of this magnitude, suggesting significant clinical and regulatory milestones ahead. Run this ratio through Solidus to see how it compares.

What This Means for BD Teams Right Now

If you're selling a platform or enabling technology asset, this is a seller's market — but it won't last. The 3400% surge reflects pent-up demand, not steady-state growth. The Merck KGaA–Bio-Techne deal will prompt every mid-cap pharma to evaluate whether they need to own their tools stack, and that creates a 6–12 month window where valuations for research tools, AI-biology platforms, and multi-modality engines will be inflated. If you're a founder or CEO of a platform biotech, start conversations now. The window is open.

If you're on the buy side, move with precision rather than speed. The risk in a zero-to-34 spike is overpaying for category heat rather than asset quality. Not every "AI biology" or "enabling platform" company deserves a $1B+ TDV. Diligence the data: how many validated programs has the platform produced? What's the hit rate? Is the technology defensible or is it a wrapper around publicly available models? Use Deal Benchmarks to reality-check the term sheets crossing your desk.

Deal structures are shifting. The notable deals table shows a mix of massive outright acquisitions (Bio-Techne), undisclosed platform partnerships (Generate:Biomedicines), and milestone-heavy licensing deals (YaoPharma). The trend favors optionality-rich structures: options to expand into additional programs, equity kickers, and co-development rights that let the buyer scale exposure as the platform proves out. Flat upfront-plus-royalty deals are losing share in this category. BD teams should be prepared to negotiate more complex term sheets with multiple decision points.

One more tactical note: the "other" category explosion means your competitive intelligence screens need recalibration. If your deal tracking filters are set to flag oncology, immunology, and rare disease only, you're missing the fastest-growing deal category of 2026. Add platform technology, research tools, and AI-biology to your alert criteria immediately.

Benchmark your deal against current market rates. Whether you're structuring upfronts, milestone schedules, or royalty tiers, the data should drive the negotiation — not gut feel. Use the Ambrosia calculator to stress-test your deal economics against the latest comparable transactions.